American Society of Hirudotherapy

Wound Healing

Clinical evidence review — the established, FDA-cleared role of leech therapy is relieving venous congestion in flap and replant salvage (~65–85%); for chronic and venous ulcers the clinical evidence is one small uncontrolled study (Bapat 1998, n=20) plus case reports, and use for chronic-wound closure is investigational

Bleeding / Transfusion Risk
Aeromonas Infection Risk
Single-Use Only + Biohazard Disposal
Last Updated: May 26, 2026ASH Editorial · based on the booksTier B — Clinical evidence (off-label)GRADE: Low
Off-label wound healing adjunct: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Limited RCT evidence: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.

Clinical Evidence — Not FDA-Evaluated

Clinical Evidence — Not FDA-Evaluated for Chronic Wounds. Medicinal leeches are FDA 510(k)-cleared for venous congestion in surgical flaps (K040187). Use in chronic wound management represents off-label application; the only PubMed-indexed clinical study for a chronic ulcer is one small uncontrolled series (Bapat 1998, n=20), and no controlled trial exists.

GRADE Evidence Level: Low

Observational studies or RCTs with serious limitations

International Clinical Evidence

The following evidence reflects international clinical experience. Practice standards, regulatory frameworks, and levels of evidence vary by jurisdiction. U.S. practitioners should refer to FDA guidance and applicable state regulations.

Part I — Epidemiology and Clinical Significance

6.5M

US patients with chronic wounds

$25B

Annual US healthcare cost

130K

Diabetes-related amputations/year

50–60%

Chronic wounds with biofilm

Chronic wounds — defined as wounds that fail to heal through normal reparative processes within 4–6 weeks — represent a major and growing healthcare burden driven by aging populations, increasing diabetes prevalence, and the obesity epidemic. The three most common types are diabetic foot ulcers (DFU), venous leg ulcers (VLU), and pressure injuries. Standard healing rates remain suboptimal: only 31% of DFUs heal within 20 weeks with standard care, and 40–60% of VLUs heal within 12 weeks with compression therapy alone.

Medicinal leech therapy has one genuinely established, FDA-cleared wound-relevant role: relieving venous congestion in compromised flaps and replants. For chronic wounds and ulcers, the clinical evidence is far more limited. The main PubMed-indexed clinical study of leech therapy for a chronic ulcer is a single small, uncontrolled series of 20 varicose-ulcer patients (Bapat et al., 1998); beyond this the literature consists of case reports and small mixed-indication case series. There is no controlled diabetic-foot-ulcer trial and no leech growth-factor (VEGF/PDGF) clinical study. Standard wound care remains primary, and leech therapy for chronic-wound closure should be regarded as investigational.

Part II — Wound Healing Biology and Leech Mechanisms

Normal wound healing proceeds through four overlapping phases. Chronic wounds become “stuck” in the inflammatory phase due to persistent infection, biofilm, poor perfusion, or metabolic factors. Leech therapy may address multiple barriers to healing simultaneously:

Healing PhaseBarrier in Chronic WoundsLeech MechanismSGS CompoundClinical Evidence
HemostasisMicrothrombosis, poor perfusionAnticoagulation + fibrinolysisHirudin (Kd = 20 fM), destabilase, calinBapat: pO₂ 40.05 mmHg in leech-extracted blood confirms targeted venous decompression
InflammationChronic inflammation, elevated MMPsProtease inhibition, anti-inflammatory cascadeEglin c (elastase inhibitor), bdellins (trypsin/plasmin inhibitors), LDTI (tryptase inhibitor)No controlled clinical evidence in surgical/chronic wounds; mechanism plausible but unproven
ProliferationReduced growth factors, impaired angiogenesisGrowth factor stimulation, vasodilationSGS → increased VEGF (angiogenesis), PDGF (fibroblast recruitment)No clinical study demonstrates leech-induced VEGF/PDGF change in human wound fluid
Infection / BiofilmBacterial colonization, biofilm persistenceAntimicrobial activityDestabilase-L (lysozyme-like activity), complement inhibitorsIn vitro antimicrobial demonstrated; clinical impact unclear
RemodelingECM disorganization, excessive fibrosisECM remodeling, scar softeningHyaluronidase (potent spreading factor), collagenase, destabilase (fibrinolysis)No clinical evidence for scar remodeling; mechanism theoretical only

Part III — Growth Factor and Tissue Oxygenation Evidence

Venous Decongestion Mechanism (Bapat, 1998)

In 20 patients with complicated varicose veins and venous ulcers, medicinal leech therapy was associated with healing of all ulcers, decreased oedema and limb girth in 95% of patients, and decreased hyperpigmentation in 75%. The partial oxygen pressure of leech-extracted blood (40.05 ± 7.24 mmHg) was similar to the patients' venous blood (34.33 ± 8.40 mmHg), indicating the leech withdraws predominantly venous blood. This supports a local venous-decongestion mechanism. There is no clinical study showing that leech therapy stimulates VEGF or PDGF in human wound fluid; that mechanism remains hypothetical, and the Bapat study was small (n = 20) and uncontrolled.

Part V — Chronic Venous Ulcers and Post-Thrombotic Wound Healing

Table 2. Evidence for hirudotherapy in chronic venous ulcers and post-thrombotic syndrome
StudyDesignPopulation (n=)InterventionKey OutcomeResult
Bapat et al.
1998
Prospective clinical study with pO₂ monitoringComplicated varicose veins with venous ulcer(s) (chronic venous insufficiency)
(n=20)
Hirudotherapy (Hirudo medicinalis) applied to the area surrounding the varicose ulcer(s); partial oxygen pressure (pO₂) of arterial and venous blood compared with leech-extracted blood (n = 7 subset)Ulcer healing, oedema/limb-girth reduction, hyperpigmentation, pO₂ of leech-extracted bloodAll ulcers healed. 95% of patients showed decreased oedema and limb girth. 75% showed decreased hyperpigmentation. Leech-extracted blood pO₂: 40.05 ± 7.24 mmHg (similar to venous blood 34.33 ± 8.40 mmHg).
The only PubMed-indexed clinical series of leech therapy for venous ulcers that we identified; the other PubMed records are single case reports (e.g., PMIDs 32670976 and 40700533). Small (n = 20), uncontrolled; the authors themselves state the finding requires confirmation by controlled trials. The mean pO₂ of leech-extracted blood (40.05 ± 7.24 mmHg) was similar to that of the patients' venous blood (34.33 ± 8.4 mmHg), indicating the leech withdraws venous blood, supporting a local venous-decongestion mechanism (PMID 9701897).

Chronic Venous Ulcers — Case-Report Level Only

No PubMed-indexed clinical study documents a high-dose leech-therapy series for chronic venous ulcers. Where leech therapy is considered for venous disease, it should be regarded as investigational and adjunctive to standard compression-based care rather than a primary high-dose protocol.

Flap Salvage (Whitaker 2012, n = 277; Herlin 2017) — Established Use

The established, wound-relevant use of medicinal leeches is relief of venous congestion in compromised flaps and replants. A systematic review of 277 reported cases found an overall salvage-success rate of 77.98% (Whitaker et al., 2012), and a systematic review of flap-salvage studies reported success rates of 65–85% (Herlin et al., 2017). No randomized controlled trials exist, so even this established use rests on observational evidence.

In flap and replant salvage, leech therapy decongests the venous-obstructed tissue while arterial inflow is preserved, buying time for venous outflow to re-establish. Aeromonas antibiotic prophylaxis (e.g. a ciprofloxacin plus trimethoprim-sulfamethoxazole combination) is required, and roughly half of reported cases needed transfusion.

Part VI — Surgical Wound Evidence

Table 3. Evidence for hirudotherapy in surgical wound healing
StudyDesignPopulation (n=)InterventionKey OutcomeResult
Whitaker et al.
2012
Systematic reviewReported clinical cases of medicinal leech use in plastic and reconstructive surgery (flaps, replants) with venous congestion
(n=277)
Medicinal leech therapy to relieve venous congestion in compromised flaps/replantsSalvage success vs failure; complications, transfusion and antibiotic requirementsOverall reported success rate 77.98% (216/277). Blood transfusion required in 49.75%; antibiotics given in 79.05%; overall complication rate 21.8%.
Synthesis of 67 papers; the review found no robust randomized controlled trials, so the evidence base is largely observational. This is the established, wound-relevant role of leech therapy — decongesting venous-compromised flaps and replants — not primary chronic-wound closure.
Herlin et al.
2016
Systematic reviewStudies of leech therapy for venous-congested pedicled or free flaps (1960–2015)
(n=41 studies)
Medicinal leech therapy for flap salvage in patent venous insufficiencyFlap-salvage success rate; treatment protocol, adjuncts, complicationsSalvage success rate ranged 65–85% (83.7% in the authors' own case series). Transfusion required in ~50%; Aeromonas antibiotic prophylaxis (ciprofloxacin + trimethoprim-sulfamethoxazole) advised.
Reliable treatment for patent venous insufficiency of pedicled/free flaps when revision surgery has failed or is not appropriate. Literature is heterogeneous; the review provides a practical dosage and antibiotic-prophylaxis protocol (PMID 27427444).

Flap/Replant Salvage — Observational Evidence Only

There is no controlled trial of leech therapy for surgical or postoperative wounds. The evidence that is verifiable in surgery concerns venous congestion in flaps and replants (Whitaker et al., 2012, 277 cases, 77.98% salvage; Herlin et al., 2017, 65–85% salvage) — a relief-of-congestion indication, not prevention of surgical-wound complications.

Mechanism (plausible, not established for surgical wounds): local venous decongestion together with salivary anticoagulant and anti-inflammatory factors may improve perfusion of congested tissue. This rationale is biologically plausible but has not been tested against surgical-wound outcomes in any controlled study, and no claim of reduced wound complications can be supported.

Part VII — Post-Traumatic Wound Healing and Scar Remodeling

There is no PubMed-indexed clinical evidence for leech therapy in post-traumatic wound healing or scar remodeling. Any use of leech therapy for post-traumatic wounds or scars is investigational and unsupported by controlled data; the following salivary components are described only for their theoretical, mechanistic rationale:

Collagenase

Enzymatic breakdown of excessive collagen in fibrotic scar tissue, promoting matrix remodeling and increased tissue flexibility.

Destabilase (Fibrinolysis)

Isopeptidase activity cleaves ε-(γ-glutamyl)-lysine bonds in stabilized fibrin within scar tissue, reducing fibrous density.

Hyaluronidase

“Spreading factor” (leech hyaluronidase, orgelase), a potent spreading factor that increases tissue permeability (Claude, 1937), facilitating SGS penetration into dense scar tissue that would otherwise be impermeable.

Part VIII — Treatment Protocols by Wound Type

ParameterDFUVLU / Varicose UlcerChronic Venous Ulcer (PTS)Surgical WoundPost-Traumatic Scar
Application sitePerilesional (1–2 cm from edge)Perilesional + along affected veinsAlong affected extremityMidpoint of suture, 1–1.5 cm from suture lineDirectly on scar tissue
Leeches / session2–44–810–201–23–4
SessionsWeekly × 8–164 over 8 weeks2–3 at 2-week intervalsAlternating days post-op5–6 every other day
DurationFull engorgementFull engorgementFull engorgementFull engorgement20 minutes (Abuladze method)
Standard careOffloading, debridement, moist dressings, glucose controlCompression therapy, debridementAnticoagulation, elevationStandard wound careRehabilitation program
Vascular assessmentABI ≥ 0.7 requiredDuplex ultrasoundDuplex ultrasound——
AntibioticsExtended prophylaxis (full course)Standard prophylaxisStandard prophylaxisPer surgical protocolStandard prophylaxis
SourceNo controlled DFU study (investigational)Bapat 1998 (uncontrolled, n=20)Case reports only (investigational)Flap salvage: Whitaker 2012, Herlin 2017No clinical evidence (investigational)

Part IX — Safety and Infection Considerations

Dual Infection Risk

Chronic wound patients face a unique dual risk: (1) pre-existing wound colonization that may be exacerbated, and (2) new Aeromonas hydrophila infection introduced by the leech. The leech endosymbiont A. hydrophila is inherently resistant to first-generation cephalosporins and ampicillin. Wound culture and targeted antibiotic prophylaxis (ciprofloxacin + TMP-SMX) are mandatory.
Risk FactorWound PopulationManagement Strategy
Immunocompromise (diabetes)DFU patientsExtended antibiotic prophylaxis
Peripheral neuropathyDFU patientsEnhanced bite-site monitoring (patient cannot feel pain from complications); visual inspection protocol
Peripheral arterial diseaseDFU, VLU patientsABI ≥ 0.7 required; leech bite wounds may not heal in critically ischemic limbs
Pre-existing wound infectionAll wound typesWound culture before initiating; treat active infection first; do not apply leeches to actively infected tissue
Anticoagulant therapyPTS, VLU patientsAdditive anticoagulant effect → excessive post-detachment bleeding. Coordinate with anticoagulation management.
Anemia risk (high-dose protocols)Chronic venous ulcer patients (up to 20 leeches/session in an uncontrolled Russian series of 67 trophic-ulcer patients, Shchekotov 1980)Hemoglobin monitoring before each session. Total blood loss per session should not exceed about 200-250 mL (roughly 35-50 mL per leech including post-detachment oozing). Transfusion is given when Hb falls below 8 g/dL in flap settings.
Contraindications specific to wound patients:

  • Active cellulitis, deep tissue infection, or osteomyelitis
  • Critical limb ischemia
  • Uncontrolled diabetes
  • Severe anemia (Hb < 8 g/dL)
  • Active sepsis
  • Wound with exposed tendon, bone, or hardware (infection risk at implant site)

Key Takeaways

1. The established, FDA-cleared wound-relevant use of medicinal leeches is relieving venous congestion in flap and replant salvage: ~78% salvage across 277 reported cases (Whitaker 2012) and 65–85% in a systematic review of flap-salvage studies (Herlin 2017). No randomized trials exist even for this use.

2. For venous ulcers, the only PubMed-indexed clinical study is small and uncontrolled: all ulcers healed and 95% had reduced oedema in 20 patients (Bapat 1998, n=20), a finding the authors said requires confirmation by controlled trials.

3. There is NO controlled trial showing that leech therapy improves healing or reduces complications of surgical or postoperative wounds; the only randomized comparison found (Mozafari 2011, 56 congested sural flaps) compared leeches with venous catheterization and concluded catheterization was more effective, easy and safe.

4. There is NO clinical study showing that leech therapy stimulates VEGF or PDGF in human wound fluid; the growth-factor mechanism is hypothetical, not demonstrated.

5. There is NO controlled diabetic-foot-ulcer trial of leech therapy; for chronic wounds beyond flap salvage the evidence is a single small study plus case reports, so this use is investigational.

6. There is NO PubMed-indexed clinical evidence for leech therapy in post-traumatic wound healing or scar remodeling.

7. The plausible mechanism is local venous decongestion plus salivary anticoagulant and anti-inflammatory factors; Bapat's pO₂ data support preferential venous-blood withdrawal, but the effect on chronic-wound outcomes is unproven.

8. Aeromonas hydrophila infection risk requires antibiotic prophylaxis (e.g. ciprofloxacin plus trimethoprim-sulfamethoxazole) whenever leeches are applied; roughly half of reported flap-salvage cases also required transfusion.

Research Agenda

  • Multicenter DFU RCT (n ≥ 100): Leech therapy + standard care vs standard care alone, stratified by Wagner grade and ABI. Primary endpoint: complete healing at 16 weeks. Secondary: time to 50% closure, amputation rate.
  • VLU RCT with standardized assessment (n ≥ 80): Using PUSH (Pressure Ulcer Scale for Healing) score, digital planimetry, and standardized photography. Include only compression-refractory patients (≥ 6 months failed therapy).
  • Wound biomarker panel study: Simultaneous measurement of VEGF, PDGF, FGF-2, TGF-β, MMP-2/9, TIMP-1/2, and inflammatory markers (IL-1β, IL-6, TNF-α) in wound fluid before and after hirudotherapy sessions.
  • Tissue oxygenation study: Transcutaneous oximetry (TcPO₂) monitoring at the wound margin during and after leech application to quantify the microcirculation enhancement in real-time.
  • Cost-effectiveness analysis : Leech therapy vs advanced wound care products (becaplermin $1,000+/course, negative pressure therapy $100–200/day) in treatment-refractory chronic wounds.
  • Scar remodeling quantification: Ultrasound elastography or durometry measurement of scar tissue stiffness before and after hirudotherapy in post-traumatic and surgical scars.
  • Regulatory Disclaimer

    Use of medicinal leeches for chronic wound management is off-label. The FDA-cleared indication is limited to venous congestion in surgical flaps (510(k) K040187). Institutional governance, informed consent, and careful patient selection are required for all wound healing applications.

    Related Research

    Clinical Literature2017

    Management of Chronic Non-healing Wounds by Hirudotherapy

    This hirudotherapy-focused article explains that chronic wounds, often defined as unhealed after three months, can remain in a prolonged inflammatory stage and cause persistent pain, and advises professional evaluation for any wound not healing within a few weeks.

    Iqbal A et al. · World journal of plastic surgery

    Clinical Literature2025

    Effective Management of Venous Ulcer with Leech Therapy: A Case Report

    A 42-year-old male with a venous ulcer near the medial malleolus received five sessions of leech therapy (three Hirudo medicinalis per session, at 10-day intervals) and achieved 80% epithelialization, 80% granulation, and a VAS pain reduction from 8 to 1.

    Wani KR, Shah HA, Ashraf A, Nazir A, Mehraj M, Ansari AN, Nayab M · Advances in mind-body medicine

    Clinical Literature2025

    Healing with integrative management of Diabetic foot ulcer - A case report

    A 50-year-old man with a two-month plantar diabetic foot ulcer was treated for three months with Ayurvedic measures including jalauka avcharana (leech bloodletting), parisheka and shamana therapy; healing time was reportedly shortened, with wound care assessed by the DMIST tool.

    Katkar R, Aadithyaraj KT, Rana U · Journal of Ayurveda and integrative medicine

    Clinical Literature2025

    Reviving ancient wisdom: exploring the effectiveness of Jalaukavacharan in pain management and wound healing — a case series

    Ayurvedic case series of four patients with infected, including some non-healing, wounds treated with jalaukavacharan (leech therapy) alongside oral antibiotics and herbal medicines. Wound healing and pain both improved steadily across all cases, supporting Jalaukavacharan's efficacy within a combined wound-management protocol.

    Gautam A et al. · Alternative therapies in health and medicine

    Clinical Literature2025

    Development of a VEGF-activated scaffold with enhanced angiogenic and neurogenic properties for chronic wound healing applications

    Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

    Palomeque Chávez et al. · Biomaterials science

    Clinical Literature2025

    From Maggots to Recovery: Exploring an Integrative Medicine Approach to Chronic Non-Healing Ulcer with Leech Therapy and Panchvalkal Ointment: A Case Study

    Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

    Dagar et al. · Alternative therapies in health and medicine

    Related Resources

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.